AKT1 and neoplasm: While yet to be trialled in melanoma patients, pre-clinical evidence demonstrated treatment of melanoma cell lines with ONC-201 reduced colony formation and migration in vitro, decreased expression of p-Akt and p-ERK, and resulted in a significant reduction in tumour volume (Wagner et al., 2017).